Experimental CAR t therapy targets tough myeloma cases

NCT ID NCT06304636

Terminated Disease control Sponsor: Cartesian Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested a new treatment called Descartes-15 for people with multiple myeloma that came back or didn't respond to standard therapies. Descartes-15 uses a patient's own immune cells, engineered to recognize and attack myeloma cells. The trial was very small (4 participants) and was terminated early, so we have limited information on how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Descartes-15 (RNA-engineered CAR T-cells targeting BCMA)
What this could lead to: If successful, this could point toward a new treatment option for patients with multiple myeloma who have run out of standard therapies.
What could go wrong: This is a very early, small Phase 1 trial (only 4 participants) that was terminated, so results are limited. The therapy may not work or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY MULTIPLE MYELOMA RELAPSED MULTIPLE MYELOMA

Contacts and locations

Locations

Center for Cancer and Blood Disorders (AON)

Bethesda, Maryland, 20817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.